Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | DNM1 | Q05193 | 8/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL293174 | 0.94 | ALDH1A1 (0.46) | ALDH1A1TDP1LMNADNM1MEN1 | |
| SCHEMBL27836473 | 0.89 | LMNA (0.48) | ALDH1A1TDP1LMNAOPRM1DNM1 | |
| SCHEMBL27942319 | 0.87 | LMNA (0.52) | ALDH1A1TDP1LMNAOPRM1DNM1 | |
| SCHEMBL27953209 | 0.87 | LMNA (0.46) | ALDH1A1TDP1LMNAOPRM1DNM1 | |
| SCHEMBL27953206 | 0.87 | LMNA (0.52) | ALDH1A1TDP1LMNAOPRM1DNM1 | |
| SCHEMBL27953219 | 0.87 | LMNA (0.52) | ALDH1A1TDP1LMNAOPRM1DNM1 | |
| SCHEMBL27942253 | 0.85 | LMNA (0.50) | ALDH1A1TDP1LMNAOPRM1DNM1 | |
| SCHEMBL27942243 | 0.85 | LMNA (0.50) | ALDH1A1TDP1LMNAOPRM1DNM1 | |
| SCHEMBL293419 | 0.85 | CA12 (0.30) | ALDH1A1TDP1 | |
| SCHEMBL28100081 | 0.85 | LMNA (0.50) | ALDH1A1TDP1LMNAOPRM1DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2086538-B1 | COMBINATION THERAPIES FOR TREATING ALZHEIMER'S DISEASE USING DIMEBON AND DONEPEZIL | MEDIVATION NEUROLOGY INC (US) | 2012-03-14 | — | — | EP | disclosed |
| EP-2420235-A1 | Methods and combination therapies for treating alzheimer's disease | Medivation Neurology, Inc. (US) | 2012-02-22 | — | — | EP | disclosed |
| WO-2010095041-A2 | COMPOSITIONS, METHODS, AND KITS FOR TREATING INFLUENZA VIRAL INFECTIONS | EXCRX (SINGAPORE) PTE.LTD. (SG) | 2010-08-26 | — | — | WO | disclosed |
| US-20100152108-A1 | METHODS AND COMBINATION THERAPIES FOR TREATING ALZHEIMER'S DISEASE | MEDIVATION NEUROLOGY, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100130537-A1 | CINNAMIDE COMPOUNDS FOR DEMENTIA | EISAI R&D MANAGEMENT CO., LTD (JP) | 2010-05-27 | — | — | US | disclosed |
| US-20100099714-A1 | AMPA and NMDA Receptor Antagonists for Neurodegenerative Diseases | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
| EP-2148673-A1 | CINNAMIDE COMPOUNDS FOR DEMENTIA | Eisai R&D Management Co., Ltd. (JP) | 2010-02-03 | — | — | EP | disclosed |
| EP-2131828-A2 | AMPA AND NMDA RECEPTOR ANTAGONISTS FOR NEURODEGENERATIVE DISEASES | Eisai R&D Management Co., Ltd. (JP) | 2009-12-16 | — | — | EP | disclosed |
| EP-2086538-A2 | COMBINATION THERAPIES FOR TREATING ALZHEIMER'S DISEASE USING I.A. DIMEBON AND DOLEPEZIL | Medivation Neurology, Inc. (US) | 2009-08-12 | — | — | EP | disclosed |
| WO-2008139984-A1 | CINNAMIDE COMPOUNDS FOR DEMENTIA | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008111590-A2 | AMPA AND NMDA RECEPTOR ANTAGONISTS FOR NEURODEGENERATIVE DISEASES | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008051599-A2 | COMBINATION THERAPIES FOR TREATING ALZHEIMER'S DISEASE USING I. A. DIMEBON AND DOLEPEZIL | MEDIVATION NEUROLOGY, INC. (US) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130537-A1 | CINNAMIDE COMPOUNDS FOR DEMENTIA | GRIN1, GRIN2A, GRIN3A | ALDH1A1 1878/4885TDP1 2369/4885LMNA 2715/4885 |
| US-20100099714-A1 | AMPA and NMDA Receptor Antagonists for Neurodegenerative Diseases | GRIN1, GRIN2A, GRIN3A | ALDH1A1 3296/4885TDP1 280/4885LMNA 3472/4885 |
| US-20100152108-A1 | METHODS AND COMBINATION THERAPIES FOR TREATING ALZHEIMER'S DISEASE | PSEN2, APP, PSEN1 | ALDH1A1 1605/4885TDP1 1536/4885LMNA 3427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.